Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $114

Benzinga · 5d ago
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $130 to $114.